Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 229 results
Filters: Author is Su, Zhaohui  [Clear All Filters]
Found 229 results.

Adult

Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM. "Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170." J. Acquir. Immune Defic. Syndr.. 2008;49(4):377-83.
Wilkin TJ, Goetz MBidwell, Leduc R, et al. "Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity." Clin. Infect. Dis.. 2011;52(7):925-8.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Vahey MT, Wang Z, Su Z, et al. "CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway." AIDS Res. Hum. Retroviruses. 2008;24(8):1047-66.
McComsey GA, Walker UA, Budhathoki CB, et al. "Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229." AIDS. 2010;24(16):2507-15.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
McLinden RJ, Paris RM, Polonis VR, et al. "Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)." AIDS. 2012;26(1):1-9.
Gulick RM, Su Z, Flexner C, et al. "Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211." J. Infect. Dis.. 2007;196(2):304-12.
Wilkin TJ, Su Z, Krambrink A, et al. "Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients." J. Acquir. Immune Defic. Syndr.. 2010;54(5):470-6.

Anti-HIV Agents

Tsibris AMN, Hu Z, Paredes R, et al. "Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures." J. Virol.. 2012;86(12):6416-26.
Tsibris AMN, Paredes R, Chadburn A, et al. "Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211." Clin. Infect. Dis.. 2009;48(5):642-9.
Su Z, Gulick RM, Krambrink A, et al. "Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211." J. Infect. Dis.. 2009;200(11):1724-8.
Tsibris AMN, Sagar M, Gulick RM, et al. "In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject." J. Virol.. 2008;82(16):8210-4.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
Wilkin TJ, Su Z, Krambrink A, et al. "Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients." J. Acquir. Immune Defic. Syndr.. 2010;54(5):470-6.
Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM. "Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170." J. Acquir. Immune Defic. Syndr.. 2008;49(4):377-83.

Pages